At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 131 enrolled
Drug / intervention
Reproxalap Ophthalmic Solution (0.25%) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The INVIGORATE 2 Trial: A Single-center, Randomized, Double-masked, Crossover Design, Vehicle-controlled, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Reproxalap Ophthalmic Solution (0.25%) Compared to Vehicle in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)
In Brief
A Phase 3 clinical trial evaluating Reproxalap Ophthalmic Solution (0.25%) and Vehicle Ophthalmic Solution for Allergic Conjunctivitis. Completed, enrolled 131 participants across 1 site.
Detailed Summary
The INVIGORATE 2 Trial: A single-center, randomized, double-masked, crossover design, vehicle-controlled, Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared to vehicle in subjects with seasonal allergic conjunctivitis using the environmental exposure chamber (EEC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesCanada
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartJan 2022
First PostedFeb 2022
Primary CompletionApr 2023
TodayJul 2026
First PostedFeb 10, 2022
Enrollment StartJan 21, 2022
Primary CompletionApr 22, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.4 years ago
Interventions
Reproxalap Ophthalmic Solution (0.25%)drug
Reproxalap Ophthalmic Solution (0.25%) dosed twice.
Vehicle Ophthalmic Solutiondrug
Vehicle Ophthalmic Solution dosed twice.